Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Torben Plesner*, Hendrik Tobias Arkenau, Francesca Gay, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan M. Schecter, Paul G. Richardson

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

17 Downloads (Pure)
OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind186
Udgave nummer3
Sider (fra-til)e35-e39
ISSN0007-1048
DOI
StatusUdgivet - aug. 2019

Citationsformater